ConductScience.org, home
Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)
API referenceFor AI assistants

Trial · NCT00095238

Results by group480

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 480

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Percentage of Participants With First Occurrence of the Composite Outcome of Death (All Cause) or Protocol-Specified Cardiovascular (CV) Hospitalization at Given TimepointsIrbesartanPercentage at 1 Year12.3percentage of participants
Percentage of Participants With First Occurrence of the Composite Outcome of Death (All Cause) or Protocol-Specified Cardiovascular (CV) Hospitalization at Given TimepointsPlaceboPercentage at 1 Year12.1percentage of participants
Percentage of Participants With First Occurrence of the Composite Outcome of Death (All Cause) or Protocol-Specified Cardiovascular (CV) Hospitalization at Given TimepointsIrbesartanPercentage at 2 Years20.7percentage of participants
Percentage of Participants With First Occurrence of the Composite Outcome of Death (All Cause) or Protocol-Specified Cardiovascular (CV) Hospitalization at Given TimepointsPlaceboPercentage at 2 Years21.3percentage of participants
Percentage of Participants With First Occurrence of the Composite Outcome of Death (All Cause) or Protocol-Specified Cardiovascular (CV) Hospitalization at Given TimepointsIrbesartanPercentage at 3 Years26.4percentage of participants
Percentage of Participants With First Occurrence of the Composite Outcome of Death (All Cause) or Protocol-Specified Cardiovascular (CV) Hospitalization at Given TimepointsPlaceboPercentage at 3 Years28.4percentage of participants
Percentage of Participants With First Occurrence of the Composite Outcome of Death (All Cause) or Protocol-Specified Cardiovascular (CV) Hospitalization at Given TimepointsIrbesartanPercentage at 4 Years32.9percentage of participants
Percentage of Participants With First Occurrence of the Composite Outcome of Death (All Cause) or Protocol-Specified Cardiovascular (CV) Hospitalization at Given TimepointsPlaceboPercentage at 4 Years34.2percentage of participants
Percentage of Participants With First Occurrence of the Composite Outcome of Death (All Cause) or Protocol-Specified Cardiovascular (CV) Hospitalization at Given TimepointsIrbesartanPercentage at 5 Years39.2percentage of participants
Percentage of Participants With First Occurrence of the Composite Outcome of Death (All Cause) or Protocol-Specified Cardiovascular (CV) Hospitalization at Given TimepointsPlaceboPercentage at 5 Years39.5percentage of participants
Percentage of Participants Experiencing Heart Failure Mortality or Heart Failure Hospitalization at Given Time PointsIrbesartanPercentage at 1 Year7.9percentage of participants
Percentage of Participants Experiencing Heart Failure Mortality or Heart Failure Hospitalization at Given Time PointsPlaceboPercentage at 1 Year8.2percentage of participants
Percentage of Participants Experiencing Heart Failure Mortality or Heart Failure Hospitalization at Given Time PointsIrbesartanPercentage at 2 Years12.9percentage of participants
Percentage of Participants Experiencing Heart Failure Mortality or Heart Failure Hospitalization at Given Time PointsPlaceboPercentage at 2 Years13.7percentage of participants
Percentage of Participants Experiencing Heart Failure Mortality or Heart Failure Hospitalization at Given Time PointsIrbesartanPercentage at 3 Years15.7percentage of participants
Percentage of Participants Experiencing Heart Failure Mortality or Heart Failure Hospitalization at Given Time PointsPlaceboPercentage at 3 Years17.2percentage of participants
Percentage of Participants Experiencing Heart Failure Mortality or Heart Failure Hospitalization at Given Time PointsIrbesartanPercentage at 4 Years19.8percentage of participants
Percentage of Participants Experiencing Heart Failure Mortality or Heart Failure Hospitalization at Given Time PointsPlaceboPercentage at 4 Years20.3percentage of participants
Percentage of Participants Experiencing Heart Failure Mortality or Heart Failure Hospitalization at Given Time PointsIrbesartanPercentage at 5 Years23.6percentage of participants
Percentage of Participants Experiencing Heart Failure Mortality or Heart Failure Hospitalization at Given Time PointsPlaceboPercentage at 5 Years23.8percentage of participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00095238/results

API referenceFor AI assistants